Otsuka America Pharmaceutical - Publications - Faculty & Research - Harvard Business School

Filter Results: (338)

Filter Results: (338)

Show Results For

← Page 12 of 338 Results →

November 1991 (Revised August 2005)
Case

Whelan Pharmaceuticals: Tax Factors and Global Site Selection

Whelan Pharmaceuticals, a U.S. company with $3 billion in sales, must decide where to manufacture its newest product. In considering possible sites, both foreign and U.S., the firm must identify and make trade-offs between tax, marketing, and manufacturing factors. View Details

Keywords: Globalized Firms and Management; Geographic Location; Cost vs Benefits; Production; Pharmaceutical Industry; United States

June 2004
Case

Aventis SA (B): A Company is Born

By: Joshua D. Margolis and Carin-Isabel Knoop

Supplements the (A) case. View Details

Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States

August 2001
Case

Scios, Inc.

By: Regina E. Herzlinger

Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States

01 Sep 2006
News

HBS Student Battles ALS

people every year, is not a high priority for either the public or pharmaceutical companies. To stimulate novel treatment ideas and to raise the venture funding needed to get those ideas to market, he launched two organizations. One is... View Details

Keywords: Business Schools & Computer & Management Training; Educational Services; Health, Social Assistance

January 2017
Case

Medtronic: Making the Big Leap Forward (A)

By: William W. George and Monica Baraldi

In 2014, Medtronic was about to execute a $50 billion acquisition of Ireland-based Covidien. Medtronic CEO Omar Ishrak was committed to building the largest medical technology company in the world while broadening its ability to fulfill its mission of “alleviating... View Details

Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States

April 2002
Article

A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany

By: Arthur A. Daemmrich

Keywords: Health; Government and Politics; Pharmaceutical Industry; United States; Germany

Find at Harvard

August 2008 (Revised May 2009)
Background Note

Note on Generic Drugs in the European Union

By: Robert C. Pozen and Elizabeth M. Leonard

Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details

Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States

Find at Harvard

13 Jul 2020
News

Locally Grown

pharmaceutical machinery sector. With the natural beauty of the Rocky Mountains as a backdrop for his career decision, Fenwick-Smith became increasingly interested in climate change and what the business community could do to make a... View Details

Keywords: April White

February 2006 (Revised February 2009)
Case

AIDS in Brazil

By: Rohit Deshpande and Ricardo Reisen de Pinho

Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details

Keywords: Price; Government and Politics; Health Care and Treatment; Health Disorders; Rights; Negotiation; Business and Government Relations; Pharmaceutical Industry; Brazil

26 Jul 2016
Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Pharmaceutical; Pharmaceutical; Pharmaceutical

February 2005 (Revised April 2006)
Case

Rx Depot: Importing Drugs from Canada

By: Debora L. Spar

In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot... View Details

Keywords: Courts and Trials; Entrepreneurship; Intellectual Property; Laws and Statutes; Pharmaceutical Industry; Canada; United States

Find at Harvard

2023
Working Paper

Market Exclusivity and Innovation: Evidence From Antibiotics

By: Edward Kong and Olivia Zhao

The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details

Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States

March 2023 (Revised March 2024)
Case

The Purdue Pharma Bankruptcy: Settling the Opioid Crisis

By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney

How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details

May 2010 (Revised June 2010)
Supplement

Pfizer: Letter from the Chairman (B)

By: Robert L. Simons and Kathryn Rosenberg

This case continues the story begun in "Pfizer: A Letter from the Chairman" (HBS No. 110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report. View Details

Keywords: Corporate Accountability; Corporate Governance; Business and Shareholder Relations; Value Creation; Decision Choices and Conditions; Annual Reports; Pharmaceutical Industry; United States

15 Jan 2018
Research & Ideas

A Better Business Model for Fighting Cancer

iPhoto With billions of dollars spent on the development of precision medicine and related cancer research over the last decade, a recent partnership seeks a new way to bring these treatments to patients more quickly: through a better business model. Founded in... View Details

Keywords: by Julia Hanna; Pharmaceutical; Pharmaceutical

October 2020
Teaching Plan

Merck: COVID-19 Vaccines

By: Willy C. Shih

COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details

Keywords: Vaccines; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Research and Development; Business Strategy; Pharmaceutical Industry; United States

September 2012 (Revised November 2014)
Case

Cialis Lifecycle Management: Lilly's BPH Dilemma

By: Elie Ofek and Natalie Kindred

How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details

Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States

July 2009 (Revised May 2010)
Case

Pfizer: Letter from the Chairman (A)

By: Robert L. Simons and Natalie Kindred

This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details

Keywords: Decision Choices and Conditions; Corporate Accountability; Corporate Governance; Annual Reports; Business and Shareholder Relations; Value Creation; Pharmaceutical Industry; United States

May 2002 (Revised October 2005)
Case

Marketing Antidepressants: Prozac and Paxil

By: Youngme E. Moon and Kerry Herman

Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details

Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States

March 1993
Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III

Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details

Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States

←
12
13
…
16
17
→